Skip to main content
Premium Trial:

Request an Annual Quote

Wyeth Using Singulex's Erenna Biomarker-Detection System

NEW YORK (GenomeWeb News) - Singulex said today that it has installed its Erenna biomarker-detection platform in Wyeth Research’s labs under its Erenna Technology Access Program.
 
The ETAP program includes the Erenna, which is used to detect and count single molecules, as well as customized immunoassay development services, reagents and software and other services. Singulex is working with Wyeth to develop immunoassays on the platform to accurately measure specific biomarkers in human blood.
 
Erenna is capable of measuring low levels and small changes of protein biomarkers in a variety of biological samples, the company said.
 
Wyeth is currently using Erenna to validate several assays “that should help us guide our clinical programs, said Ole Vesterqvist, senior director of Wyeth’s Biomarker Laboratory in Clinical Translational Medicine, in a statement.
 
Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.